1530 wright

16
Restaging the Primary Tumor Cameron Wright, MD Thoracic Surgery MGH 2012 Focus on Thoracic Surgery: Lung Cancer

Upload: dragon-yott

Post on 14-Jun-2015

121 views

Category:

Health & Medicine


1 download

TRANSCRIPT

Page 1: 1530 wright

Restaging the Primary Tumor

Cameron Wright, MDThoracic Surgery

MGH2012 Focus on Thoracic Surgery:

Lung Cancer

Page 2: 1530 wright

Disclosures

None

Page 3: 1530 wright

CT Characteristics of Locally Advanced Disease

• Pleural effusion and nodularity-suggestive of M1a disease-thoracentesis or VATS exploration and biopsy

• Chest wall invasion-signs of invasion include bone destruction, pleural thickening, loss of extrapleural fat plane, tumor extending into the chest wall and extensive contact between chest wall and tumor. Only bone destruction is 100% accurate.

• Mediastinal invasion-invasion of mediastinal fat, extensive contact with the mediastinal pleura (> 3 cm) or aorta (>90 degree ) suggestive of invasion. However unless there is extensive invasion CT is often unreliable.

Page 4: 1530 wright

4

LLL Adenocarcinoma with Pleural Metastases in Fissure

Page 5: 1530 wright

5

NCCN Restaging Guidelines

• Restaging after induction therapy is difficult to interpret, but CT +/- PET should be performed to exclude disease progression or interval development of metastatic disease

• Radiographic methods have a poor positive and negative predictive values in the evaluation of the mediastinum after neoadjuvant therapy

• Recommendations are category 2A

Page 6: 1530 wright

6

Comparison of Pathologic and Radiographic Response-INT-0160• Phase II trial of induction chemoradiotherapy for superior

sulcus tumors

• 2 cycles of cisplatin and etoposide with concurrent 45 Gy of radiation

• 83 patients underwent thoracotomy

• 46% had a partial radiographic response, 54% stable disease

• 34% had a pCR, 31% had microscopic residual disease, and 35% had gross residual disease

• 35% with stable radiographic disease had a pCR!

• 38% with a partial radiographic response had a pCR!

Rusch VW et al. JTCVS 2001;121:472-83

Page 7: 1530 wright

7

Meta Analysis-Use of PET to Predict Tumor Response

Author Prevalence of Residual Disease

Sensitivity Specificity PPV NPV

CerfolioSUV>3

9% 97% 100% 100% 67%

OhtsukaCR>0.25

80% 89%

PortSUV ↓ 50%

24% 100% 58% 43% 100%

RyuSUV> 3

74% 88% 67% 88% 67%

YamamotoSUV>4.5

88% 89% 78% 94%

Rebollo-Aguire AC et al. J Surg Oncol 2010;101:486-94.

Page 8: 1530 wright

8

Timing of Restaging PET/CT

• Retrospective review of accuracy of PET/CT in staging patients after induction CT/RT

• 109 patients (90% N2)

• 50% ↓ Max SUV considered to be a complete response

• ROC analysis suggested optimum time for restaging was 26 days

• PET issues-not standardized, amount FDG given, scanning technique, glucose level, etc

Cerfolio RJ, Bryant AS. Ann Thorac Surg 2007;84:1092-7.

Page 9: 1530 wright

9

T4N0M0 SVC Involvement before and after Induction CT/RT

Page 10: 1530 wright

10

T4 SVC Postinduction Pathology

• FINAL PATHOLOGIC DIAGNOSIS:

• A. RIGHT UPPER LOBE, LUNG LOBECTOMY:

• Squamous cell carcinoma. See synoptic report.

• B. SUPERIOR VENA CAVA, EXCISION:

• Squamous cell carcinoma invading vessel wall.

Page 11: 1530 wright

11

LUL T3N1M0 Before and After CT/RT

Pre Post

Post

Page 12: 1530 wright

12

T3N1 Postinduction Pathology

• FINAL PATHOLOGIC DIAGNOSIS:

• A. LUNG PNEUMONECTOMY, LEFT:

• Squamous cell carcinoma (4.4 cm), moderately differentiated, s/p chemoradiation

• with approximately 30% of tumor mass showing necrosis.

• Note: The tumor invades the hilar fat but the inked soft tissue resection

• margins are free.

Page 13: 1530 wright

13

LUL Adenocarcinoma with RLN Involvement (T4N0M0)

Page 14: 1530 wright

14

T4 LUL after Induction CT/RT

Page 15: 1530 wright

15

T4 LUL Pathology

• FINAL PATHOLOGIC DIAGNOSIS:

• A. LUNG PNEUMONECTOMY, LEFT:

• HISTOLOGIC TYPE (modified WHO classification): Adenocarcinoma, acinar poorly

• differentiated, two small foci of residual carcinoma (each approximately 1 cm)

• amidst extensive necrosis secondary to therapy).

• TUMOR SIZE (MAXIMUM DIAMETER): 10 cm.

Page 16: 1530 wright

16

Bottom Line

• Confirm absence disease progression and distant metastatic disease with appropriate scans

• Review preinduction imaging for areas that lead to a concern for a complete resection

• Review postinduction imaging to confirm absence of progressive disease and any response to therapy, especially in areas for concern about resectability

• Exploration is always the final common denominator and often leads to findings that are better then what the CT suggests